organ revenu growth eas investor concern
softer growth management also issu better outlook
remaind year lift underli revenu guidanc
share ralli day trade sideway post
continu like abt well-round portfolio modest execut risk
co face much tougher comp second half need
deliv improv vs libr
alin remain pois outperform could risk meet
investor expect challeng comp felt low-to-mid
fair valu view share fairli valu time
segment result mix overal devic result better
strong ep momentum cardiac map confirm ou
structur heart momentum mitraclip flip side neuromod
result came light reportedli due salesforc chang
sale also mark hamper replac cycl
headwind tough comparison pacer side
diabet continu libre- management reiter libr
expect compani estim
world-wide user libr track exit year
think could conserv mix manag note
user type attribut momentum new user
rather competit win neutral
could tct next catalyst data coapt trial tct
septemb could trade opportun given complic trial
design feel expect widespread plan survey
investor expect confer
valuat maintain neutral rate risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
report revenu grow organ come
similar estim devic nutrit segment
came model establish pharma diagnost result
bit light
nutrit sale grew quarter driven strength ou
busi ensur glucerna brand establish pharma revenu
increas out-performance continu target market india
china turn diagnost alin launch europ outperform
result competit win strong custom retent aler
manag comment see much growth
busi yet perform trend intern expect
medic devic result trend favor vs model better result
seen ou structur heart electrophysiolog diabet flip
side neuromod result fell short compani point
difficult comparison mri-pac side well replac cycl
headwind within icd manag ad expect result
flat remaind final neuromod result also fell short
model manag attribut weak part recent chang
salesforc
ebit margin vs forecast main driver
upsid lower margin vs forecast told ep
exceed estim
actualsbtig estimate variancetot incom net bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
make number chang estim revenu flow
rais estim nutrit electrophysiolog structur heart
diabet trim neuromod estim
downsid lastli incorpor greater fx headwind
particularli previous estim
keep margin estim rel unchang flow
beat rais adj ep estim
abbott rate neutral share appreci strong new
product launch continu back half although
see valu product think upsid investor expect
decreas feel target multipl ntm earn appropri
mirror histor rang last year appli
month ep estim yield enough upsid buy rate btig
provid price target neutral-r stock
risk rate includ multipl expans competit healthcar polici
chang currenc fluctuat healthcar fall favor fda
regulatori agenc product delay failur execut merger synergi
exhibit comp tabl large-cap peer
net ep gross bpsadj ebit bp btig estim compani filingsnewold changecagrntm johnsonjnjund fishertmobuy bdxnot scientificbsxbuy factset data btig estimatesintra-day price ex-amortcompanytickerr ptpricemarket cap bev/sal
abbott incom statement sale ex oper interest incom incom tax expens net ep methodology/abt share net incom ep incl disc marginsgross expensescog oper expens ep btig estim compani report
abbott segment laboratori y/i laboratori y/i growth laboratori y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth diagnost y/i diagnost y/i growth diagnost y/i growthy/i growth oper adj aleretot y/i y/i growth y/i growth oper adj btig estim
abbott segment devicesrhythm manag y/i manag y/i growth manag y/i growth y/i y/i growth y/i growth failur y/i failur y/i growth failur y/i growth y/i y/i growth y/i growth heart y/i heart y/i growth heart y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth devic y/i devic y/i growth devic y/i growth totaltot report segment us y/i report segment y/i report segment ww y/i btig estim compani adjust stj acquisit optic divestitur
btig cover compani mention report
appendix analyst certif import disclosur
